全文获取类型
收费全文 | 119130篇 |
免费 | 6753篇 |
国内免费 | 709篇 |
专业分类
耳鼻咽喉 | 1181篇 |
儿科学 | 3859篇 |
妇产科学 | 2676篇 |
基础医学 | 16974篇 |
口腔科学 | 4246篇 |
临床医学 | 10708篇 |
内科学 | 26957篇 |
皮肤病学 | 3113篇 |
神经病学 | 11626篇 |
特种医学 | 2773篇 |
外国民族医学 | 1篇 |
外科学 | 10696篇 |
综合类 | 452篇 |
现状与发展 | 1篇 |
一般理论 | 51篇 |
预防医学 | 11914篇 |
眼科学 | 1957篇 |
药学 | 8325篇 |
中国医学 | 462篇 |
肿瘤学 | 8620篇 |
出版年
2024年 | 130篇 |
2023年 | 1154篇 |
2022年 | 2461篇 |
2021年 | 4151篇 |
2020年 | 2524篇 |
2019年 | 3512篇 |
2018年 | 4012篇 |
2017年 | 2985篇 |
2016年 | 3400篇 |
2015年 | 3818篇 |
2014年 | 5025篇 |
2013年 | 6522篇 |
2012年 | 9889篇 |
2011年 | 10243篇 |
2010年 | 5615篇 |
2009年 | 4717篇 |
2008年 | 8095篇 |
2007年 | 8067篇 |
2006年 | 7418篇 |
2005年 | 7026篇 |
2004年 | 6248篇 |
2003年 | 5623篇 |
2002年 | 5080篇 |
2001年 | 690篇 |
2000年 | 537篇 |
1999年 | 737篇 |
1998年 | 885篇 |
1997年 | 710篇 |
1996年 | 617篇 |
1995年 | 507篇 |
1994年 | 472篇 |
1993年 | 393篇 |
1992年 | 356篇 |
1991年 | 251篇 |
1990年 | 255篇 |
1989年 | 216篇 |
1988年 | 211篇 |
1987年 | 172篇 |
1986年 | 180篇 |
1985年 | 135篇 |
1984年 | 159篇 |
1983年 | 154篇 |
1982年 | 164篇 |
1981年 | 128篇 |
1980年 | 130篇 |
1979年 | 86篇 |
1978年 | 85篇 |
1977年 | 81篇 |
1976年 | 65篇 |
1974年 | 55篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
Munzone E Nolé F Goldhirsch A Botteri E Esposito A Zorzino L Curigliano G Minchella I Adamoli L Cassatella MC Casadio C Sandri MT 《Clinical breast cancer》2010,10(5):392-397
BackgroundHER2/neu status of tumor cells at metastatic sites in patients with advanced disease may differ from that of the primary tumor. Assessing the presence of target antigens on circulating tumor cells (CTCs) might affect treatment choice.Patients and MethodsFrom June 2007 to October 2008, we collected 23 mL of blood from each of the 76 consecutive patients before and during chemotherapy to determine CTC numbers and HER2 overexpression. CTCs were isolated with the CellSearch System® (Veridex, LLC; Raritan, NJ) and fluorescently stained with the Epithelial Cell Kit®. Tumor Phenotyping Reagent® was used to investigate HER2/neu overexpression.ResultsConcordance of HER2 status between the primary tumor and CTCs was 86% (49 out of 57 patients) at baseline and 82% (50 out of 61 patients) in the treatment samples. HER2 overexpression in CTCs was acquired in 8 out of 45 patients (18%) and lost in 3 out of 16 patients (19%) during a treatment containing trastuzumab. The overall discordance rate between the primary tumor and CTCs was 18% (11 out of 61 patients). Patients with HER2 overexpression in CTCs had poorer progression-free survival compared with those without CTCs or with HER2? CTCs (log-rank P =.036).ConclusionInformation on the presence or absence of HER2 overexpression can be obtained in CTCs. Larger trials are needed to evaluate the activity of HER2-targeted therapy in patients with acquired HER2 overexpression in CTCs. 相似文献
993.
994.
995.
Tampellini M Berruti A Bitossi R Gorzegno G Alabiso I Bottini A Farris A Donadio M Sarobba MG Manzin E Durando A Defabiani E De Matteis A Ardine M Castiglione F Danese S Bertone E Alabiso O Massobrio M Dogliotti L 《Breast cancer research and treatment》2006,98(3):241-248
Summary Tumor response to first-line chemotherapy in advanced breast cancer offers prognostic information and may be used as a surrogate marker for evaluating treatment efficacy. With this study we wanted to determine whether changes in circulating serum CA 15-3 levels during chemotherapy provided additional information for prognostic prediction. Serum CA 15-3 was measured at baseline and after 3 and 6 months during anthracycline-based first-line chemotherapy in 526 patients with advanced breast cancer prospectively enrolled in five phase II-III trials. Changes in marker levels were correlated with disease response, time to progression and overall survival. In all, 336 patients attained a disease response. A significant relationship was found between disease response and CA 15-3 variations, although many individual discrepancies were also observed. At the 6-month time point, the median time to progression was 15.3 months in patients with normal marker levels throughout the study, 11.7 months in those with a CA15-3 reduction >25%, 9.6 months in those with elevated baseline CA 15-3 levels which did not change during therapy and 8.6 months in those with increased marker levels (p < 0.001). The median survival was 42.3, 29.7, 28.5, and 24.8 months, respectively (p < 0.002). The prognostic role of changes in CA 15-3 levels was maintained in the patient subset attaining disease response or stabilization to treatment (p < 0.001) and after adjusting for clinical response and major prognostic parameters in the multivariate analysis (p < 0.001). In conclusion, monitoring serum CA 15-3 levels during first-line chemotherapy in advanced breast cancer patients provides prognostic information independently from tumor response. 相似文献
996.
Federica Perrone Simona Suardi Elisa Pastore Paola Casieri Marta Orsenigo Stefano Caramuta Gianpaolo Dagrada Marco Losa Lisa Licitra Paolo Bossi Samantha Staurengo Maria Oggionni Laura Locati Giulio Cantu Massimo Squadrelli Antonino Carbone Marco A Pierotti Silvana Pilotti 《Clinical cancer research》2006,12(22):6643-6651
PURPOSE: The aim of this study was to acquire further insights into the pathogenetic pathways of head and neck squamous cell carcinomas (HNSCC) that may be useful for identifying new biomarkers instrumental in developing more specific treatment approaches. EXPERIMENTAL DESIGN: Cell cycle regulators and epidermal growth factor receptor (EGFR) and BRAF genes were analyzed in a series of 90 oropharyngeal SCCs of a cohort of surgically treated patients from a single institution, and the results were matched with the presence of high-risk human papillomavirus (HR-HPV) DNA and the TP53 status. RESULTS: At least four distinct groups of tumors were identified sharing a common histology but displaying different molecular/cytogenetic patterns: (a) 19% were HPV-positive SCCs whose lack of alterations of the investigated genes could explain their particular natural history, which requires less aggressive treatment; (b) 37% were HPV-negative SCCs carrying TP53 mutations, which may be more effectively treated by drugs acting through p53-independent apoptosis; (c) 34% were HPV-negative SCCs carrying wild-type TP53 and loss of 9p21 (p16INK4a and p15INK4b) and/or cyclin D1 overexpression that justify treatment with DNA-damaging drugs followed by cell cycle inhibitors; and (d) 10% were HPV-negative lacking tumor suppressor genes and cell cycle alterations. The second, third, and fourth groups also showed an increased copy number of EGFR and chromosome 7 (43%) that might justify the additional or alternative use of EGFR inhibitors. CONCLUSIONS: Our findings suggest that assessing HPV, TP53, 9p21, and EGFR status may be crucial to finding more tailored and beneficial treatments for oropharyngeal SCCs. 相似文献
997.
998.
Pantalone O Palladino F Lotito RM Missere M Savino G Minella G Meduri A Natale L Marano P 《Rays》2003,28(1):13-19
The introduction of spiral multislice or multidetector CT (MSCT) has led to significant results in coronary diagnostic imaging. In fact with MSCT, isotropic (cubic voxel) three-dimensional imaging of large volumes (e.g. the entire cardiac volume) was possible in a single breath-hold. Moreover, with dedicated reconstruction algorithms, temporal resolution and scannable volume could be optimized, limiting the artifacts associated with the spiral technique. The quantification of calcium deposits in the coronary walls and, in particular, the morphologic study of these vessels represent an important challenge to this technique. Multislice CT with retrospective gating is now a relevant diagnostic instrument in coronary heart disease; however only most recent CT devices with 16 rows of detectors enable a real solution of problems of spatial (isotropic, submillimetric imaging) and temporal (< 0.5 s rotation time) required for correct identification of stenosis and plaque characterization, which are the two main goals of noninvasive coronary imaging. 相似文献
999.
Inherited variation in circadian rhythm genes and risks of prostate cancer and three other cancer sites in combined cancer consortia 下载免费PDF全文
Fangyi Gu Han Zhang Paula L. Hyland Sonja Berndt Susan M. Gapstur William Wheeler the ELLIPSE consortium Christopher I. Amos Stephane Bezieau Heike Bickeb?ller Hermann Brenner Paul Brennan Jenny Chang‐Claude David V Conti Jennifer Anne Doherty Stephen B Gruber Tabitha A Harrison Richard B Hayes Michael Hoffmeister Richard S Houlston Rayjean J. Hung Mark A. Jenkins Peter Kraft Kate Lawrenson James McKay Sarah Markt Lorelei Mucci Catherine M. Phelan Conghui Qu Angela Risch Mary Anne Rossing H.‐Erich Wichmann Jianxin Shi Eva Schernhammer Kai Yu Maria Teresa Landi Neil E. Caporaso 《International journal of cancer. Journal international du cancer》2017,141(9):1794-1802
Circadian disruption has been linked to carcinogenesis in animal models, but the evidence in humans is inconclusive. Genetic variation in circadian rhythm genes provides a tool to investigate such associations. We examined associations of genetic variation in nine core circadian rhythm genes and six melatonin pathway genes with risk of colorectal, lung, ovarian and prostate cancers using data from the Genetic Associations and Mechanisms in Oncology (GAME‐ON) network. The major results for prostate cancer were replicated in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial, and for colorectal cancer in the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO). The total number of cancer cases and controls was 15,838/18,159 for colorectal, 14,818/14,227 for prostate, 12,537/17,285 for lung and 4,369/9,123 for ovary. For each cancer site, we conducted gene‐based and pathway‐based analyses by applying the summary‐based Adaptive Rank Truncated Product method (sARTP) on the summary association statistics for each SNP within the candidate gene regions. Aggregate genetic variation in circadian rhythm and melatonin pathways were significantly associated with the risk of prostate cancer in data combining GAME‐ON and PLCO, after Bonferroni correction (ppathway < 0.00625). The two most significant genes were NPAS2 (pgene = 0.0062) and AANAT (pgene = 0.00078); the latter being significant after Bonferroni correction. For colorectal cancer, we observed a suggestive association with the circadian rhythm pathway in GAME‐ON (ppathway = 0.021); this association was not confirmed in GECCO (ppathway = 0.76) or the combined data (ppathway = 0.17). No significant association was observed for ovarian and lung cancer. These findings support a potential role for circadian rhythm and melatonin pathways in prostate carcinogenesis. Further functional studies are needed to better understand the underlying biologic mechanisms. 相似文献
1000.
Frequency and phenotypic spectrum of germline mutations in POLE and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas 下载免费PDF全文
Isabel Spier Stefanie Holzapfel Janine Altmüller Bixiao Zhao Sukanya Horpaopan Stefanie Vogt Sophia Chen Monika Morak Susanne Raeder Katrin Kayser Dietlinde Stienen Ronja Adam Peter Nürnberg Guido Plotz Elke Holinski‐Feder Richard P. Lifton Holger Thiele Per Hoffmann Verena Steinke Stefan Aretz 《International journal of cancer. Journal international du cancer》2015,137(2):320-331
In a number of families with colorectal adenomatous polyposis or suspected Lynch syndrome/HNPCC, no germline alteration in the APC, MUTYH, or mismatch repair (MMR) genes are found. Missense mutations in the polymerase genes POLE and POLD1 have recently been identified as rare cause of multiple colorectal adenomas and carcinomas, a condition termed polymerase proofreading‐associated polyposis (PPAP). The aim of the present study was to evaluate the clinical relevance and phenotypic spectrum of polymerase germline mutations. Therefore, targeted sequencing of the polymerase genes POLD1, POLD2, POLD3, POLD4, POLE, POLE2, POLE3 and POLE4 was performed in 266 unrelated patients with polyposis or fulfilled Amsterdam criteria. The POLE mutation c.1270C>G;p.Leu424Val was detected in four unrelated patients. The mutation was present in 1.5% (4/266) of all patients, 4% (3/77) of all familial cases and 7% (2/30) of familial polyposis cases. The colorectal phenotype in 14 affected individuals ranged from typical adenomatous polyposis to a HNPCC phenotype, with high intrafamilial variability. Multiple colorectal carcinomas and duodenal adenomas were common, and one case of duodenal carcinoma was reported. Additionally, various extraintestinal lesions were evident. Nine further putative pathogenic variants were identified. The most promising was c.1306C>T;p.Pro436Ser in POLE. In conclusion, a PPAP was identified in a substantial number of polyposis and familial colorectal cancer patients. Screening for polymerase proofreading mutations should therefore be considered, particularly in unexplained familial cases. The present study broadens the phenotypic spectrum of PPAP to duodenal adenomas and carcinomas, and identified novel, potentially pathogenic variants in four polymerase genes. 相似文献